Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Presage Biosciences

Request full access

Presage Biosciences develops a technology platform to improve the cancer drug development process

Seattle, United StatesFounded 2008Biotech & Life Sciences

About Presage Biosciences

Presage Biosciences, founded in 2008 as a spin-off from the Fred Hutchinson Cancer Research Center, is a translational oncology company focused on de-risking and accelerating cancer drug development. The company was established by Dr. Jim Olson, a pediatric oncologist who sought a better way to determine effective cancer therapies. Dr. Olson's frustration with the limitations of preclinical models in predicting human responses to treatment led to the creation of Presage. He holds an M.D. and a Ph.D. from the University of Michigan and has founded two other biotech companies.

The core of Presage's business is its proprietary Comparative In Vivo Oncology (CIVO®) platform. This technology addresses a critical bottleneck in oncology: the high failure rate of drugs in clinical trials, often because preclinical models do not accurately reflect the complex human tumor microenvironment. The CIVO® device allows for the intratumoral microdosing of up to eight different drugs or drug combinations directly into a patient's solid tumor before surgery. These microdoses, approximately 1/100th of a standard therapeutic dose, are delivered with fluorescent trackers, enabling researchers to observe cellular and molecular responses within the native tumor environment without subjecting the patient to systemic toxicity. After a set period, the tumor is surgically removed and analyzed to assess drug efficacy, resistance, and potential synergies.

Presage operates on a business model centered around strategic partnerships with pharmaceutical and biotechnology companies. It provides access to its CIVO® platform to help these partners validate new drug targets, identify effective drug combinations, and select the right patient populations for later-stage clinical trials. This is done through Phase 0 studies, which are exploratory trials designed to gather early human data before committing to more expensive and lengthy Phase I trials. The company generates revenue through these collaborations, which have included major players like Merck, AstraZeneca, Bristol Myers Squibb, and Takeda. Having raised a total of $35 million in equity, the company is backed by venture funds and strategic investors, including LabCorp Venture Fund and Takeda Ventures.

Source: Dealroom company data

Presage Biosciences in the Seattle ecosystem

Live from Dealroom

The Presage Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • David Wu

Series B and later6 investors entered at this stage

  • Takeda Ventures
  • Celgene
  • Bristol-Myers Squibb
  • Takeda
  • LabCorp
  • InHarv Partners
Team profiled 10 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Presage Biosciences on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Presage Biosciences on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.